03/13/2026
Competition in the weight-loss medication market is driving significant price reductions for popular GLP-1 drugs like Wegovy and Ozempic.
Drugmaker Novo Nordisk has announced lower pricing for these medications, aiming to improve affordability and expand access for patients who rely on GLP-1 therapies for weight management. Experts say the price reduction could help many patients who previously struggled to afford treatment, especially as some insurance plans have reduced coverage for weight-loss medications.
🔗 Read the full article:
Bariatric surgery is a one-time procedure that delivers transformative, long-term results, while GLP-1 medications require expensive, lifelong monthly injections.